about
Targeting immune checkpoints in malignant gliomaU87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissuesImmunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production.Combining cytotoxic and immune-mediated gene therapy to treat brain tumorsAntibody-based immunotherapy for malignant glioma.Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape.Glioma-associated cancer-initiating cells induce immunosuppression.Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Therapeutic activity of NK cells against tumors.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research.Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomasRandomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastomaNovel therapeutics in adult malignant brain gliomas.Dendritic cell-based immunotherapy for malignant gliomas.Immunotherapy for malignant glioma: current approaches and future directions.Immunotherapy for human glioma: innovative approaches and recent results.A review of vaccine clinical trials for non-small cell lung cancer.Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.Intramedullary nailing as a 'second hit' phenomenon in experimental research: lessons learned and future directionsEradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.Immunotherapy for the treatment of glioblastoma.Vaccine-based immunotherapy for glioblastoma.Current challenges in designing GBM trials for immunotherapy.Therapeutic potential and challenges of natural killer cells in treatment of solid tumorsVaccine-based immunotherapeutic approaches to gliomas and beyond.Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model.From apoptosis to autoimmunity: insights from the signaling pathways leading to proliferation or to programmed cell death.Tumor therapy by immune recruitment with bispecific antibodies.Transcriptional regulation of the transforming growth factor-beta2 gene in glioblastoma cells.Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cellsSubstance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system.Production of a bioactive high molecular weight transforming growth factor beta-like molecule by human malignant glioma cell lines.Immunobiology of gliomas: new perspectives for therapy.Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.
P2860
Q28072012-546B7E72-A462-4F46-B167-F503D9ECF11AQ28674494-4A6E8332-951B-40A9-8FB4-DF2D080F7FFDQ30989272-2D364F0A-F2C2-4A1E-8538-B6ECF9A516E7Q31013320-780C87AA-416E-422B-9F59-D742F158D78CQ34120472-6BCAF049-19EB-41D9-BEB7-CED8592650E5Q34136498-4F0BB20E-988D-4C85-8620-6E0A9478064EQ34147415-C324738E-F457-4B5B-8163-841E75EEB981Q34480557-CAFA448C-95BA-494D-B90E-06AEF7EE91BBQ34552162-755AD26C-6322-4243-B7C3-6B72D5466377Q35113661-0630A50E-9419-4B0E-9984-A55D2604A021Q35682205-BD9FAA31-97BB-4C53-A2C4-F203BE4861FCQ35796211-2BB75BAB-DBBB-47F8-B890-9282DFCBD08CQ36079507-DA276E21-8071-4BE3-8CB2-8E9ECB69C08CQ36187046-4E07B7FB-E056-4767-A100-36297DC94A36Q36198607-5604FF0C-586C-4EEF-BE93-A6FCC8739D75Q36273693-5A72ACC5-E19B-4FAA-81B8-A6F753DFFDE8Q36284489-5A9BC209-6603-453E-8CCD-96C1050775B8Q36675454-3DAAC982-66B2-4E15-8916-9EFED4741A40Q37161091-23F47F47-3733-49B1-8E5C-8ABAC74C518AQ37655310-267533A6-095B-476D-89A3-E1956540608FQ37680355-8E33233C-7615-4970-8670-487B0809F005Q37952245-712A7C92-4AED-4604-AE0B-0905F414DD3DQ37980026-B4383D38-5CC8-4DB8-8A11-1041FB1BAE2AQ38233114-A56C5B08-AC8B-4EE0-8053-A96AD5B5DD52Q38313826-6E0917BF-67B2-49E4-815B-A4BDC880649DQ38478878-D54F2614-DE2E-4E48-AA01-47EC800399EAQ38789860-6B98018D-89AE-4CA9-8A74-E4E188CAA8FEQ39279856-99191C39-7C0D-4B38-B3B2-0EA886C4B34BQ39813239-B2E2CF6D-88EA-4DC8-9451-0EE9D07CFBE2Q39924722-C8DC9A9C-0B13-424B-BD44-4658275A04ECQ40399256-15E462A3-CC45-4074-8642-6C7F443A5819Q40433289-31265C28-8324-4DB4-88CE-A240201FC30FQ40759126-44C6F1E2-8CAB-4178-99F6-0CBE264C514EQ40851222-D774106D-E15E-4E96-BFBA-40D825A7AD4AQ40980907-34F24A76-5A25-48EC-96B3-8BF5DF869F39Q41264607-48F384BF-F0E3-4FA3-86DB-33E316B1AF33Q41417768-BE473344-3844-4583-AF40-667C976AEC3DQ41503973-A3D5B3BA-DEE3-4AF5-8143-0D4B4C219741Q41650683-C3A4B85D-1D88-4A77-BDA9-A0502BDA0E03Q41826343-C076AD97-5828-4276-88F3-EA1252454CC7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modulation of T-cell function by gliomas.
@en
Modulation of T-cell function by gliomas.
@nl
type
label
Modulation of T-cell function by gliomas.
@en
Modulation of T-cell function by gliomas.
@nl
prefLabel
Modulation of T-cell function by gliomas.
@en
Modulation of T-cell function by gliomas.
@nl
P2093
P1433
P1476
Modulation of T-cell function by gliomas.
@en
P2093
P304
P356
10.1016/0167-5699(91)90068-5
P577
1991-10-01T00:00:00Z